Rudolf Hyrdel, Michal Demeter, Jana Božíková, Peter Bánovčin jr, Peter Hyrdel, Ján Janík, Ľudovít Laca, Martin Schnierer
In the past neuroendocrine tumors (NET) were rare. Higher interest of their diagnostics and treatment has brought an unexpected increase of incidence (In the last 30 years 400 % increase!). Thanks to improved diagnostics and introduction of hormonal therapy with somatostatin analogs survival of patients has improved significantly as well as their quality of lives (1). It is the reason of enormous increase of NET prevalence. At present NET of GIT is the second most frequent tumor disease of digestive tract, after stomach carcinoma, with double prevalence as pancreas cancer (2). Endosonography plays the main role in successful diagnosis. Using E-US we are able to localize NET smaller than 10 mm, which cannot be localized in 40-60 % by conventional imaging methods (USG, CT, AG, MR, PET and Octreoscan). Line E-US enables to take target cytologic samples that help to establish the diagnosis of NET. The authors emphasize advantages of E-US diagnostics presenting more cases, that could not be diagnosed without E-US.